A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Tafenoquine is an investigational 8-aminoquinoline for the prevention of Plasmodium vivax relapse. Tafenoquine has a long half-life and the potential for more convenient dosing, compared with the currently recommended 14-day primaquine regimen.This randomized, active-control, double-blind trial was...

Celý popis

Uloženo v:

Podrobná bibliografie
Hlavní autoři:	Mark M Fukuda, Srivicha Krudsood, Khadeeja Mohamed, Justin A Green, Sukhuma Warrasak, Harald Noedl, Ataya Euswas, Mali Ittiverakul, Nillawan Buathong, Sabaithip Sriwichai, R Scott Miller, Colin Ohrt
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Public Library of Science (PLoS) 2017-01-01
Edice:	PLoS ONE
On-line přístup:	http://europepmc.org/articles/PMC5679603?pdf=render
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

A randomized, double-blind, active-control trial to evaluate the efficacy and safety of a three day course of tafenoquine monotherapy for the treatment of Plasmodium vivax malaria.

Podobné jednotky